Drugs / JNJ-77474462
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252520 | May → Nov 2023 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT04544826 | Oct 2020 → Aug 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04544813 | Oct 2020 → May 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-77474462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252520 ↗ |
| Route | Intravenous | “single subcutaneous (SC) or intravenous (IV) administrations” NCT04544813 ↗ |
| Route | Subcutaneous | “single subcutaneous (SC) or intravenous (IV) administrations” NCT04544813 ↗ |